News Headlines Article

Review of prostate cancer drug Provenge renews medical cost-benefit debate
Washington Post

Federal officials are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

The Centers for Medicare & Medicaid Services, which dictate what treatments the massive federal health-insurance program for the elderly will cover, is running a “national coverage analysis” of Provenge, the first vaccine approved for treating any cancer.

Commands